Home
About Us
Corporate Profile
Milestones
Investment Partners
Corporate News
Products
Technological Innovation
Product Description
Guideline & Consensus
Sustainalibity
Corporate Values
Investor Relations
Discipline Development
Join Us
Contact Us
Language
简体中文
English
Key words:
News
RuiNing RuiXun | RuiNing Bio’s “Embolization Hydrogel” has been awarded the “2026 Outstanding Product Innovation Award” at the 15th CFS Financial Summit.
The second session of the “Injectable Absorbable Isolation Hydrogel Training Course” at the Tumor Center of Tongji Hospital, Huazhong University of Science and Technology, has concluded successfully.
New progress in deepening Shanghai–Xinjiang medical cooperation: Xinjiang’s first case of precision radiotherapy for prostate cancer assisted by Respacio® has been successfully performed.
The “Absorbable Isolation Hydrogel Injection Training Course” concluded successfully at the Oncology Center of Tongji Hospital, affiliated with Huazhong University of Science and Technology.
The inauguration ceremony of the Fudan–RuiNing Bio–ZuQuan “Future Intelligent Hydrogel Industry–University Joint Laboratory” was held successfully.
Respacio® isolation gel from Ruining Bio has been deployed for its first clinical use in cervical cancer patients at Wuhan Union Hospital.